The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population-based case-control study.

IF 2.2 4区 医学 Q2 DERMATOLOGY Australasian Journal of Dermatology Pub Date : 2024-08-13 DOI:10.1111/ajd.14359
Anna Lyakhovitsky, Boaz Amichai, Eran Galili, Arnon Cohen, Khalaf Kridin, Zvi Segal, Doron Netzer
{"title":"The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population-based case-control study.","authors":"Anna Lyakhovitsky, Boaz Amichai, Eran Galili, Arnon Cohen, Khalaf Kridin, Zvi Segal, Doron Netzer","doi":"10.1111/ajd.14359","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a long-standing debate if finasteride, a medication used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA), can cause psychiatric side effects.</p><p><strong>Objective: </strong>The goal of this large-scale population-based study was to determine whether finasteride therapy for BPH and AGA is associated with the emergence of mental health conditions.</p><p><strong>Methods: </strong>This observational case-control study compared the data from patients with BPH who received finasteride 5 mg daily and patients with AGA who received finasteride 1 mg daily with age- and gender-matched controls. The incidence of psychological health outcomes such as depression, anxiety, neuroses, bipolar disorder, schizophrenia, psychoses and alcohol abuse within 2 years of the initiation of finasteride therapy has been evaluated and compared between the finasteride groups and controls.</p><p><strong>Results: </strong>The BPH group included 307 men with a mean age of 61.5 (±17.4) years and 1218 controls. Mental health outcomes recorded in 2.3% of the patients, with no significant increase in rate when compared to controls. The AGA group consisted of 23,227 men with a mean age of 31.4 (±10.3) years and 39,444 controls. Only One percent of AGA patients developed psychiatric disorders. In comparison to controls, patients with AGA had higher rates of anxiety and depression (0.6% vs. 0.4%, p = 0.04, and 0.5% vs. 0.4%, p = 0.007, respectively). In multivariate regression models, finasteride was found as one of the risk factors for anxiety (OR 1.449, p = 0.002) and depression (OR 1.439, p = 0.003) when stratified to age, sector, socioeconomic status and comorbidities.</p><p><strong>Conclusions: </strong>According to our research, finasteride users had a very low rate of adverse mental health effects, with no increase in psychological sequelae in BPH patients and a slight increase in anxiety and depression in AGA patients.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.14359","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is a long-standing debate if finasteride, a medication used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA), can cause psychiatric side effects.

Objective: The goal of this large-scale population-based study was to determine whether finasteride therapy for BPH and AGA is associated with the emergence of mental health conditions.

Methods: This observational case-control study compared the data from patients with BPH who received finasteride 5 mg daily and patients with AGA who received finasteride 1 mg daily with age- and gender-matched controls. The incidence of psychological health outcomes such as depression, anxiety, neuroses, bipolar disorder, schizophrenia, psychoses and alcohol abuse within 2 years of the initiation of finasteride therapy has been evaluated and compared between the finasteride groups and controls.

Results: The BPH group included 307 men with a mean age of 61.5 (±17.4) years and 1218 controls. Mental health outcomes recorded in 2.3% of the patients, with no significant increase in rate when compared to controls. The AGA group consisted of 23,227 men with a mean age of 31.4 (±10.3) years and 39,444 controls. Only One percent of AGA patients developed psychiatric disorders. In comparison to controls, patients with AGA had higher rates of anxiety and depression (0.6% vs. 0.4%, p = 0.04, and 0.5% vs. 0.4%, p = 0.007, respectively). In multivariate regression models, finasteride was found as one of the risk factors for anxiety (OR 1.449, p = 0.002) and depression (OR 1.439, p = 0.003) when stratified to age, sector, socioeconomic status and comorbidities.

Conclusions: According to our research, finasteride users had a very low rate of adverse mental health effects, with no increase in psychological sequelae in BPH patients and a slight increase in anxiety and depression in AGA patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
患有良性前列腺增生症和雄激素性脱发的非那雄胺使用者患精神疾病的风险:一项基于人群的病例对照研究。
背景:非那雄胺是一种用于治疗良性前列腺增生症(BPH)和雄激素性脱发症(AGA)的药物,关于非那雄胺是否会导致精神疾病副作用的争论由来已久:这项大规模人群研究的目的是确定非那雄胺治疗良性前列腺增生症和雄激素性脱发症是否与精神健康状况的出现有关:这项观察性病例对照研究比较了每天服用5毫克非那雄胺的良性前列腺增生患者和每天服用1毫克非那雄胺的AGA患者与年龄和性别匹配的对照组的数据。研究还评估了非那雄胺治疗开始后 2 年内抑郁、焦虑、神经官能症、躁郁症、精神分裂症、精神病和酗酒等心理健康后果的发生率,并将非那雄胺治疗组与对照组进行了比较:良性前列腺增生症组包括 307 名男性,平均年龄为 61.5 (±17.4) 岁,对照组包括 1218 名男性。2.3%的患者出现了心理健康问题,与对照组相比,比例没有显著增加。AGA组包括23227名男性(平均年龄为31.4(±10.3)岁)和39444名对照组。只有1%的AGA患者出现精神障碍。与对照组相比,AGA 患者患焦虑症和抑郁症的比例更高(分别为 0.6% 对 0.4%,p = 0.04;0.5% 对 0.4%,p = 0.007)。在多变量回归模型中,发现非那雄胺是导致焦虑症(OR 1.449,p = 0.002)和抑郁症(OR 1.439,p = 0.003)的危险因素之一,并与年龄、部门、社会经济地位和合并症进行了分层:根据我们的研究,非那雄胺使用者的心理健康不良反应率非常低,良性前列腺增生患者的心理后遗症没有增加,而AGA患者的焦虑和抑郁略有增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.20
自引率
5.00%
发文量
186
审稿时长
6-12 weeks
期刊介绍: Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.
期刊最新文献
A reply to: 'Melanoma documented arising in an involuting naevus 3 years after cessation of monitoring'. Interleukin-17 inhibitors for the management of severe rosacea. Re: The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA): A population-based case-control study. Dermoscopic features of the normal vermilion in skin of colour. JAK inhibitors in refractory dermatomyositis: A case series.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1